Caitlin E Martin1, Caroline Shadowen2, Bhushan Thakkar3, Travis Oakes4, Tamas S Gal5, F Gerard Moeller6. 1. Virginia Commonwealth University, (Department of Obstetrics & Gynecology, Institute for Drug and Alcohol Studies), Richmond, (Virginia), USA. 2. Virginia Commonwealth University, (School of Medicine), Richmond, (Virginia), USA. 3. Virginia Commonwealth University, (Department of Obstetrics & Gynecology), Richmond, (Virginia), USA. 4. Virginia Commonwealth University, (Clinical Research Informatics Group, C. Kenneth and Dianne Wright Center for Clinical and Translational Research), Richmond, (Virginia), USA. 5. Virginia Commonwealth University, (Department of Biostatistics, School of Medicine), Richmond, (Virginia), USA. 6. Virginia Commonwealth University, (Department of Psychiatry, Institute for Drug and Alcohol Studies), Richmond, (Virginia), USA.
Abstract
PURPOSE OF REVIEW: Opioid-related deaths are a leading cause of mortality during pregnancy through 12 months postpartum. Buprenorphine use during pregnancy is increasing, yet expert opinion on its dosing through the perinatal period is limited. We provide a review of the current clinical literature on buprenorphine dosing during pregnancy through 12 months postpartum. and present data from a retrospective chart review of patients at our institution describing trends in buprenorphine dosing during pregnancy and postpartum. Utilizing this information, we synthesize findings to provide clinical recommendations for providers. RECENT FINDINGS: Existing literature during pregnancy reflects how many women increase and split total daily buprenorphine doses as gestational age advances. SUMMARY: We present data from a retrospective chart review of patients at our institution describing trends in buprenorphine dosing during pregnancy and postpartum. Utilizing this information, we synthesize findings to provide clinical recommendations for providers. Changes in the total daily dose of buprenorphine used across pregnancy and through 12 months postpartum at the individual level do not follow consistent patterns, highlighting substantial individual variability. Altogether, buprenorphine dosing should be individualized through pregnancy and postpartum with frequent evaluations by providers and solicited input from patients.
PURPOSE OF REVIEW: Opioid-related deaths are a leading cause of mortality during pregnancy through 12 months postpartum. Buprenorphine use during pregnancy is increasing, yet expert opinion on its dosing through the perinatal period is limited. We provide a review of the current clinical literature on buprenorphine dosing during pregnancy through 12 months postpartum. and present data from a retrospective chart review of patients at our institution describing trends in buprenorphine dosing during pregnancy and postpartum. Utilizing this information, we synthesize findings to provide clinical recommendations for providers. RECENT FINDINGS: Existing literature during pregnancy reflects how many women increase and split total daily buprenorphine doses as gestational age advances. SUMMARY: We present data from a retrospective chart review of patients at our institution describing trends in buprenorphine dosing during pregnancy and postpartum. Utilizing this information, we synthesize findings to provide clinical recommendations for providers. Changes in the total daily dose of buprenorphine used across pregnancy and through 12 months postpartum at the individual level do not follow consistent patterns, highlighting substantial individual variability. Altogether, buprenorphine dosing should be individualized through pregnancy and postpartum with frequent evaluations by providers and solicited input from patients.
Entities:
Keywords:
Buprenorphine; addiction; opioid use disorder; postpartum; pregnancy; women
Authors: Christine A Pace; Leah B Kaminetzky; Michael Winter; Debbie M Cheng; Kelley Saia; Jeffrey H Samet; Alexander Y Walley Journal: J Subst Abuse Treat Date: 2014-05-02
Authors: D L Bogen; J M Perel; J C Helsel; B H Hanusa; M Romkes; T Nukui; C R Friedman; K L Wisner Journal: Psychopharmacology (Berl) Date: 2012-08-25 Impact factor: 4.530
Authors: Linda Nguyen; Laura R Lander; Kevin E O'Grady; Patrick J Marshalek; Adrienne Schmidt; Audra K Kelly; Hendrée E Jones Journal: Am J Addict Date: 2018-02-23